DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

SPORANOX (itraconazole), 1818
SPRYCEL (dasatinib), 1732
Squamous cell carcinoma (SCC)
bleomycin for, 1823
prevention of, sunscreens and, 1828
SR 16234, 1756, 1759
SR 49059, 715t, 717
SR 121463A, 715t
SREBP. See Sterol regulatory element–
binding protein (SREBP)
SSR 149415, 715t, 717
SSR240612, 932
structure of, 928t
SSRIs. See Selective serotoninreuptake
inhibitors (SSRIs)
Stabilization, of poisoned patient, 82
Staphylococcal infections, penicillin
for, 1486
Staphylococcus aureus, pyoderma
caused by, 1817
Staphylococcus aureus, ABC
transporter in, 100f
Stargardt syndrome, 104t
Statins, 752–753, 885, 892–898,
896–897
absorption, metabolism, and
excretion of, 895–896
as antianginal agents, 752
cardioprotective effects of, 894–895
chemistry of, 893–894, 893f
and coagulatoin, 895
combination therapy, with
ezetimibe, 904
combination therapy with other
lipid-lowering drugs, 898,
903
contraindications to, 897
and C-reactive protein, 895
dosage of, required to achieve
reduction in LDL-C, 895t
drug interactions with, 896–897
and endothelial function, 895
and HDL-C levels, 894
hepatic transporters and, 109
hepatotoxicity, 896
history of, 893
and inflammation, 895
and LDL-C levels, 894, 895t
and lipoprotein oxidation, 895
mechanism of action of, 894
myopathy caused by, 896
and plaque stability, 895
polymorphisms and response to,
159t, 160t, 161t
and pregnancy, 897
and reproductive health, 897
Statins (Cont.):
rhabdomyolysis caused by, 896
safety of, 897
selection of, 897
structure of, 893f
therapeutic uses of, 897–898
triglyceride reduction by, 894
and vascular dysfunction, 808
Stavudine, 1626t
absorption of, 1633
antiviral activity of, 1633
chemistry of, 1633
distribution of, 1633
drug interactions with, 1634
elimination of, 1633
mechanism of action of, 1633
pharmacokinetics of, 1630t
precautions with, 1634
resistance to, 1633
therapeutic uses of, 1634
untoward effects of, 1633–1634
Steady-state distribution, 32
Steatorrhea, 1346
Stem cell factor (SCF), 1070t
Stent(s), drug-eluting, 772
Stents, drug-eluting, 23
Stereoisomers, 43
Steroid(s)
ocular effects of, 1789, 1792
topical, for pruritus, 1828t
toxicity of, 1789
Steroidogenesis
inhibitors, 1766–1767
pathways, 1766, 1766f
Steroid receptor superfamily, 1809
Steroids, polymorphisms and response
to, 159t
Steroid synthesis, 127
Steroid X receptor (SXR), 97
Sterol regulatory element–binding
protein (SREBP), 883, 902
Sterol regulatory element–binding
protein (SREBP) cleavage
activating protein, 883
STI 565 (imatinib mesylate), 1732
Stimulant laxatives, 1333–1334
STN. See Solitary tract nucleus (STN)
Stomach
defenses against acid, 1310
ethanol and, 637
opioids and, 497
platelet-activating factor and, 955
Stomach cancer, drugs for,
1668t–1670t
Stool-wetting agents, 1333
Stop codon, 148f
Stratum corneum
barrier function, 1803, 1804f
age and, 1806
drug penetration through,
1804–1805
reservoir function, 1803, 1804f
structure and function of, 1803,
1804f
thickness, 1803, 1804f
Streptococcal infections, penicillin for,
1486
Streptococcus pyogenes, pyoderma
caused by, 1817
Streptogramins, 1535–1537
Streptokinase, 866
pharmacokinetics of, 1889t
Streptomycin, 1517
Streptozocin, 1668t–1670t
Stress-related ulcers, 1321
Stress response, ACTH secretion and,
1214
STROMECTOL (ivermectin), 1819
Stromelysin-1 polymorphism, 161t
Strongyloides stercoralis, 1445–1446,
1456
Structure-activity relationships, drug
design and, 43–44
Study design, pharmacogenetic,
151–165
Subcorneal pustular dermatosis,
dapsone for, 1823
Subcutaneous administration,
20t, 22
Sublingual administration, 21
Submucosal plexus, 174, 175
Subscription, in prescription, 1879
Substance abuse. See Drug abuse and
addiction
Substance P, 172, 182
and vasopressin secretion, 704
Substance P receptor antagonists, as
antinausea agent, 1344
Substituted urea(s), for neoplastic
disease, 1668t–1670t
Substrates, transporters and,
93, 94f
Succimer, 1874
as antidote, 86t
Succinimides, 596
Succinylcholine
action of, 260
characteristics of, 264t
dosing of, 265t
histamine and, 914
paralysis with, 261
structure of, 259f
2073
INDEX